XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues [1] $ 58,170 $ 50,645    
Sterilization and Disinfection Control [Member]        
Revenues     $ 58,170  
Clinical Genomics [Member]        
Revenues [2]       $ 50,645
Consumables [Member] | Transferred at Point in Time [Member]        
Revenues 33,010 27,471    
Hardware and Software [Member] | Transferred at Point in Time [Member]        
Revenues 14,075 13,277    
Service [Member] | Transferred at Point in Time [Member]        
Revenues 11,085 9,897    
Operating Segments [Member] | Sterilization and Disinfection Control [Member]        
Revenues [1],[3] 22,957 [4] 15,927    
Operating Segments [Member] | Clinical Genomics [Member]        
Revenues [1] 11,404 13,369    
Operating Segments [Member] | Biopharmaceutical Development [Member]        
Revenues [1] 12,008 9,889    
Operating Segments [Member] | Calibration Solutions [Member]        
Revenues [1] 11,801 11,460    
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]        
Revenues 20,396 [4] 13,707    
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]        
Revenues 8,112 8,769    
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]        
Revenues 3,922 4,486    
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]        
Revenues 580 509    
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]        
Revenues 169 [4] 81    
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]        
Revenues 2,183 3,427    
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]        
Revenues 4,837 2,691    
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]        
Revenues 6,886 7,078    
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]        
Revenues 2,392 [4] 2,139    
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]        
Revenues 1,109 1,173    
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]        
Revenues 3,249 2,712    
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]        
Revenues $ 4,335 $ 3,873    
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the acquisition of Agena Bioscience, Inc. on October 20, 2021.
[3] Includes post-acquisition GKE results during the three months ended June 30, 2024.
[4] Revenues of $6,254 from GKE are included in the Sterilization and Disinfection Control division during the three months ended June 30, 2024.